Co-amilofruse (furosemide and amiloride) (Tablets)
Non Formulary
Combination products should be avoided, unless compliance is an issue
Co-amilozide
Non Formulary
Co-triamterzide
Non Formulary
Cyclopenthiazide (Navidrex®)
Non Formulary
Diamorphine
Non Formulary
Diumide-K Continus®
Non Formulary
Dyazide®
Non Formulary
Frusene®
Non Formulary
Furosemide with triamterene
Non Formulary
Indapamide (Natrilix-SR®)
Non Formulary
Kalspare®
Non Formulary
Lasikal®
Non Formulary
Lasilactone®
Non Formulary
Navispare®
Non Formulary
Neo-NaClex-K®
Non Formulary
Spironolactone with furosemide
Non Formulary
Torasemide
Non Formulary
Triamterene (Dytac®)
Non Formulary
Xipamide (Diurexan®)
Non Formulary
Key
Restricted Drug
Unlicensed
Link to adult BNF
Link to children's BNF
Link to SPCs
Cytotoxic Drug
Controlled Drug
High Cost Medicine
Cancer Drugs Fund
NHS England
Homecare
ICB
Low carbon footprint
Medium carbon footprint
High carbon footprint
Status
Description
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry.
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry.
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist.
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information.
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use.
